AB Science S.A. (0Q77.L) LSE

1.21

-0.012(-0.98%)

Updated at September 05 04:04PM

Currency In EUR

AB Science S.A.

Address

3, Avenue George V

Paris, 75008

France

Phone

33 1 47 20 00 14

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

40

First IPO Date

October 19, 2012

Key Executives

NameTitlePayYear Born
Mr. Alain Moussy MBACo-Founder, Chairman, President, Chief Executive Officer, MD & Scientific Director625,000N/A
Mr. Christian FASSOTTEGlobal Chief Medical Officer0N/A
Dr. Albert Ahn D.V.M.President of USA Operations0N/A
Mr. Alexis BERNARDHead of Veterinary Sales0N/A
Mr. Laurent Guy MBAChief Financial Officer0N/A
Mr. Harshad KULKARNIHead of Statistics0N/A

Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.